Charles Schwab Investment Management Inc. Buys 741 Shares of Neurogene Inc. (NASDAQ:NGNE)

Charles Schwab Investment Management Inc. increased its position in Neurogene Inc. (NASDAQ:NGNE) by 2.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,317 shares of the company’s stock after purchasing an additional 741 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.23% of Neurogene worth $1,272,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Quest Partners LLC bought a new stake in shares of Neurogene in the 2nd quarter worth $55,000. SG Americas Securities LLC purchased a new stake in Neurogene in the third quarter worth approximately $150,000. Rhumbline Advisers bought a new position in shares of Neurogene during the 2nd quarter valued at $491,000. Avoro Capital Advisors LLC purchased a new position in shares of Neurogene in the 2nd quarter worth $802,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Neurogene in the second quarter worth $1,107,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Rachel Mcminn bought 47,500 shares of the stock in a transaction dated Friday, November 22nd. The shares were purchased at an average price of $20.40 per share, with a total value of $969,000.00. Following the completion of the acquisition, the chief executive officer now owns 1,297,859 shares of the company’s stock, valued at $26,476,323.60. This represents a 3.80 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christine Mikail Cvijic purchased 24,000 shares of Neurogene stock in a transaction on Friday, November 22nd. The stock was bought at an average price of $20.48 per share, for a total transaction of $491,520.00. Following the completion of the acquisition, the chief financial officer now owns 76,844 shares in the company, valued at $1,573,765.12. The trade was a 45.42 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 120,270 shares of company stock worth $2,720,249 over the last ninety days. Corporate insiders own 9.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on NGNE shares. William Blair reissued an “outperform” rating on shares of Neurogene in a report on Tuesday, November 19th. Leerink Partners increased their price objective on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Stifel Nicolaus boosted their target price on shares of Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Neurogene in a research report on Monday, November 25th. Finally, Robert W. Baird lifted their price target on shares of Neurogene from $54.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $60.83.

Neurogene Stock Performance

NGNE opened at $23.72 on Wednesday. The firm’s fifty day moving average is $38.62 and its 200 day moving average is $38.53. Neurogene Inc. has a fifty-two week low of $12.49 and a fifty-two week high of $74.49.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.